Manulife Financial (0945) AI Stock Analysis

Company Guidance

The company reiterated its medium‑term/2027 guidance and capital priorities: an 18%+ core ROE ambition (Q2 core ROE 16.3%, +130 bps YoY), a 2.5% ongoing share‑buyback program, and on‑track 2027 remittances, supported by strong capital and leverage metrics (LICAT 136%, ≈$26B excess of supervisory target; financial leverage 22.2% vs. 25% medium‑term target). Management expects Canada insurance experience to trend to neutral by year‑end, corporate results to be a loss of $300–$400M (likely toward the high end), and an expense‑efficiency medium‑term target below 45% (44.5%); operating and growth metrics cited include APE sales +21% YoY (Asia +21%, Hong Kong +37%, Canada +23%, U.S. +12%), new business CSM +16% YoY, CSM balance +20%, Global WAM net inflows $0.4B, core EPS +16% (core earnings +12% YoY; Asia core earnings +21%; Global WAM core earnings +9%), adjusted book value per share $41.12 (+15% YoY), core EBITDA margin 31.2% (+110 bps), and details on the LTC transaction ($3.2B of reserves at 80% quota share, ~−5% IFRS cede / ~6–7% NAIC cede, CAD 30M foregone core earnings in year 1), which reduces LTC morbidity risk by 24% while current LTC claim savings exceed 6% and the retained block is expected to start generating capital over the next 5–10 years.